Key result
Successful implantation of a subcutaneous implantable cardioverter defibrillator and a leadless pacemaker was achieved in a Japanese patient with recurrent prosthetic valve endocarditis.
Why the study?
Patients with bradycardia pacing indications are typically excluded from S-ICD therapy, prompting the combination of an S-ICD with a leadless pacemaker to overcome this limitation.
Case Report (n=1)
The combination of a leadless pacemaker and S-ICD can be successfully implanted in patients with recurrent prosthetic valve endocarditis who require both bradycardia pacing and defibrillation.
Supports feasibility of combined devices in recurrent prosthetic valve endocarditis; hypothesis-generating and should not yet alter practice.
The subcutaneous implantable cardioverter defibrillator (S-ICD) system was developed for defibrillation therapy that does not affect the heart and vasculature. S-ICD is preferred over transvenous ICD for patients with a history of recurrent infection presenting with life-threatening rhythms. Patients with bradycardia pacing indications are excluded from S-ICD therapy, as S-ICD lacks the capability of defibrillation in this patient group. Implantation of an S-ICD with a leadless pacemaker (LP) was proposed to overcome this issue. We describe the first case of successful implantation of S-ICD and LP in a Japanese patient with a history of recurrent prosthetic valve endocarditis.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2019) conducted a case report in Prosthetic valve endocarditis (n=1). Combination of a leadless pacemaker and subcutaneous implantable cardioverter defibrillator was evaluated on Successful implantation. Successful implantation of a subcutaneous implantable cardioverter defibrillator and a leadless pacemaker was achieved in a Japanese patient with recurrent prosthetic valve endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: